|1.||Bisson, Jonathan I: 2 articles (01/2010 - 01/2007)|
|2.||Tedeschini, Enrico: 1 article (04/2011)|
|3.||Papakostas, George I: 1 article (04/2011)|
|4.||Levkovitz, Yeciel: 1 article (04/2011)|
|5.||Katz, R J: 1 article (02/2001)|
|6.||Crockett, B: 1 article (02/2001)|
|7.||Davidson, J R: 1 article (02/2001)|
|8.||Hidalgo, R B: 1 article (02/2001)|
|9.||Connor, K M: 1 article (02/2001)|
|10.||Malik, M: 1 article (02/2001)|
|1.||Phobic Disorders (Phobia)
08/01/1997 - "Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study."
08/01/1997 - "The safety and efficacy of brofaromine, a reversible and selective monoamine oxidase inhibitor, were examined in a multicenter trial of 102 outpatients with social phobia. "
01/01/1995 - "Social phobia has also been shown to improve on treatment with either moclobemide or brofaromine. "
12/01/1995 - "Fifty-seven patients with social phobia completed a 12-week double-blind, placebo-controlled trial with the reversible and selective monoamine oxidase A inhibitor brofaromine 150 mg/day. "
11/01/1995 - "Seventy-seven patients with a primary diagnosis of social phobia (DSM-III-R) were randomized to treatment with the reversible and selective monoamine oxidase type A inhibitor brofaromine (n = 37) or placebo (n = 40) for 12 weeks in a double-blind trial. "
|2.||Post-Traumatic Stress Disorders (PTSD)
12/01/1995 - "A large multi-center, double-blind, parallel trial to assess the efficacy of brofaromine in the treatment of post traumatic stress disorder (PTSD) failed to show a significant difference between the brofaromine and placebo treatment groups. "
02/01/2001 - "2. Data from two comparable, double-blind, placebo-controlled studies of brofaromine in patients with PTSD were combined. "
12/01/1995 - "A double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of post-traumatic stress disorder."
02/01/2001 - "4. Brofaromine may have therapeutic benefit in treating PTSD, with lower baseline levels of reexperiencing and avoidance/numbing and overall less severe PTSD most predictive of outcome."
02/01/2001 - "3. Treatment response was significantly associated with lower baseline scores on the full scale Clinician-Administered PTSD Scale (CAPS) and on CAPS subscales B (re-experiencing) and C (avoidance/numbing), as well as to drug treatment with brofaromine. "
|3.||Panic Disorder (Panic Attack)
11/01/1992 - "The therapeutic efficacy of brofaromine--a new reversible and short acting MAO-A inhibitor--was evaluated in 14 inpatients with a panic disorder. "
08/01/1996 - "A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder."
01/01/1995 - "Moreover, there are encouraging results with the use of brofaromine and moclobemide in panic disorder. "
01/01/1993 - "MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. "
11/01/1992 - "Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A."
|4.||Sleep Initiation and Maintenance Disorders (Insomnia)
03/01/1994 - "In the patients who completed the trial, brofaromine was well tolerated with the exception of insomnia. "
01/01/1993 - "This study of a fixed-dose design and 6 weeks' duration found that brofaromine was significantly better than placebo on the Overall Evaluation of Efficacy, Beck self-rating scale, HAM-D Bech subscale, HAM-D total 14 items (minus the three sleep items), HAM-D depressed mood item and retardation factor, and worse than placebo on the insomnia items of HAM-D. "
06/01/1999 - "The effects of trazodone on subjective and objective sleep parameters were compared to those of placebo in a double-blind design in seven patients who developed insomnia during treatment with the selective and reversible MAO-A inhibitor, brofaromine. "
08/01/1997 - "Side effects more common with brofaromine than placebo included insomnia, dizziness, dry mouth, anorexia, tinnitus, and tremor. "
01/01/1993 - "In this study 30 patients with PD with or without agoraphobia (DSM-III-R) were treated with the selective and reversible MAO-A inhibitor brofaromine (150 mg daily) in a 12-week double-blind placebo controlled design. "
01/01/1993 - "This paper reports a randomized, double-blind, 8-week trial in which the efficacy and safety of brofaromine was compared to clomipramine in patients with panic disorder with or without agoraphobia. "
02/01/1994 - "The use of the reversible monoamine oxidase-A inhibitor brofaromine in social phobia complicated by panic disorder with or without agoraphobia."
|1.||Monoamine Oxidase (MAO)
|3.||Monoamine Oxidase Inhibitors (Monoamine Oxidase Inhibitor)
|2.||Drug Therapy (Chemotherapy)